US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% JNJ $256.03 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Immuneering Corporation

< Previous 1 2 3 Next >
News headline image
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Participation in February Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Morgan Stanley Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
< Previous 1 2 3 Next >